22
Participants
Start Date
January 31, 2017
Primary Completion Date
December 31, 2019
Study Completion Date
January 29, 2021
BHV-0223
35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
Placebo
a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
Connecticut Mental Health Center, New Haven
Collaborators (1)
Biohaven Pharmaceuticals, Inc.
INDUSTRY
Yale University
OTHER